Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xlife Sciences AG's EPS (Basic) for the
six
months ended in Dec. 2025 was CHF-3.23.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.76.
During the past 3 years, the average EPS without NRIGrowth Rate was -16.70% per year.
During the past 8 years, Xlife Sciences AG's highest 3-Year average EPS without NRI Growth Rate was -16.70% per year. The lowest was -284.30% per year. And the median was -63.60% per year.
Xlife Sciences AG (XSWX:XLS) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Xlife Sciences AG Earnings per Share (Diluted) Related Terms
Xlife Sciences AG Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG Earnings per Share (Diluted) Chart
XSWX:XLS vs VRTX, REGN, ALNY: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Xlife Sciences AG's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's PE Ratio distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's PE Ratio falls into.
Xlife Sciences AG Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Xlife Sciences AG's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-3.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of CHF-3.76 mean?
Xlife Sciences AG (XSWX:XLS) has a Earnings per Share (Diluted) of CHF-3.76 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #983 out of 1168 companies in the Biotechnology industry, placing it in the top 84.2%.
Is Xlife Sciences AG's Earnings per Share (Diluted) too high?
Xlife Sciences AG's current Earnings per Share (Diluted) is CHF-3.76. Based on the distribution chart, Xlife Sciences AG ranks #983 out of 1168 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #983 out of 1168 companies for Earnings per Share (Diluted). This places Xlife Sciences AG in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Earnings per Share (Diluted) is CHF-3.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.21, compared to a current price of CHF17.50 — trading 142.7% above its estimated fair value. The current Earnings per Share (Diluted) is CHF-3.76. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Earnings per Share (Diluted) is CHF-3.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF17.50 is trading 142.7% above its estimated GF Value™ of CHF7.21.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Earnings per Share (Diluted): CHF-3.76
GF Value™: CHF7.21 vs. price of CHF17.50 (142.7% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score
Get the complete analysis for XSWX:XLS
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
